ARTRYA LIMITED (AYA)
Share Price Analysis and Chart

03/10/2024

1

Initiation of coverage with Buy

$2.21

402.27%

Petra Capital initiates coverage on AI health-tech play, Artrya, with a Buy rating and $2.21 target.

The company's next generation deep machine learning solutions (branded Salix) are a point-of-care offering providing rapid result delivery to clinicians and are targeting a large and rapidly growing cardiac CT diagnosis market, explains the broker.

Radiologist shortages and increased scan volumes have seen AI become a cornerstone technology for diagnostic imaging companies aiming to lift margins and increase workflow efficiency, highlights Petra Capital.

After a hiccup in 2022, with the FDA knocking-back its first 510(k) process (Premarket Notification), the broker anticipates highly likely 1Q 2025 regulatory clearance of Artrya's first commercial product in the US. Salix has already been launched in Australia.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -149.60 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.10 cents.